X4 Xolremdi Granted Marketing Authorization in EU as First WHIM-Targeted Therapy
First WHIM-Targeted Therapy in the EU
The European Commission (EC) authorized Xolremdi (mavorixafor) on April 27, 2026, for increasing circulating mature neutrophils and lymphocytes in patients aged 12 years and older with WHIM syndrome. This final marketing authorization followed a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) on February 26. Due to the rare nature of the disease, the approval was granted under exceptional circumstances. The marketing authorization holder is Norgine B.V., and the developer is X4 Pharmaceuticals (XFOR). This is the first and only approved therapy targeting the underlying cause of WHIM syndrome in the EU, following the U.S. approval.
CXCR4 Antagonist Resolves Leukocyte Stagnation in Bone Marrow
Mavorixafor is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist that blocks the binding of CXCL12 to CXCR4, thereby alleviating myelokathexis—the excessive retention of neutrophils and lymphocytes in the bone marrow. Conventional treatment has focused on symptom management using granulocyte colony-stimulating factor (G-CSF), immunoglobulins, and prophylactic antibiotics combined with infection treatment. In contrast, Xolremdi offers a differentiated approach by directly inhibiting the overactive CXCR4 signaling central to WHIM's pathophysiology. With no competing approved therapies for the same indication, early competition will likely depend more on patient diagnosis rates and the effectiveness of current standard-of-care treatments than on new drug entrants.
Infection Burden Reduced in 31-Patient Phase 3 Trial
The approval was based on the global 4WHIM Phase 3 trial (NCT03995108), which randomized 31 patients aged 12 years and older to mavorixafor (n=14) or placebo (n=17) and followed them for 52 weeks. The time above the absolute neutrophil count threshold was 15.0 hours versus 2.8 hours, and the time above the absolute lymphocyte count threshold was 15.8 hours versus 4.6 hours, both with p-values <0.001. The annualized infection rate was 1.7 versus 4.2, a 60% reduction, with a nominal p-value of 0.007. The median duration of infection was 8.5 days versus 32.0 days. While the small patient population is a limitation, it is managed under the exceptional approval and post-marketing data collection requirements. However, the improvement in leukocyte counts translating into a real reduction in infections enhances the clinical credibility of the therapy.
Norgine's Distribution Network Will Determine Commercialization Speed
X4 granted Norgine Pharma UK Limited exclusive commercialization rights for the European Economic Area, the UK, Switzerland, Australia, and New Zealand in January 2025. The agreement includes an upfront payment of EUR 28.5 million, potential regulatory, commercial, and sales milestones up to EUR 226 million, and tiered royalties on net sales ranging from double digits to a mid-20% peak. X4's 2025 net product sales of Xolremdi in the U.S. were USD 6.5 million, and the WHIM market is projected to grow from USD 9.2 million in 2024 to USD 16.1 million in 2035 across the U.S., EU4, UK, and Japan. Therefore, the speed of royalty and milestone realization will depend more on securing drug pricing and reimbursement at the national level, patient identification, and Norgine's rare disease distribution capabilities than on the EU approval itself.
From an investor perspective, the EU approval marks a key regulatory milestone for X4 Pharmaceuticals (XFOR), enabling the potential realization of EUR 226 million in milestone payments and royalties peaking at mid-20%. The 4WHIM Phase 3 trial demonstrated a 60% reduction in annualized infection rates, from 4.2 in the placebo group to 1.7 in the mavorixafor group, providing evidence that CXCR4 antagonism not only improves blood cell counts but also reduces patient burden. For researchers and clinicians, the approval introduces the first oral, causative-targeting therapy to complement the current standard of care, which is centered on G-CSF, immunoglobulins, and antibiotics. However, given the 31-patient trial and the exceptional approval, long-term safety and real-world data will remain critical. As a ultra-rare disease with a 2024 market size of USD 9.2 million across seven major markets, short-term revenue will be limited. However, the absence of approved competing therapies and Norgine's European distribution network offer advantages for expanding patient diagnosis and securing mid-to-long-term market leadership.
Source: EMA (ema)